Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Valeant Commits $200,000 to Support Hurricane Relief Efforts

Valeant Pharmaceuticals International,Inc.
Posted on: 15 Sep 17
Valeant Commits $200,000 to Support Hurricane Relief Efforts

PR Newswire

LAVAL, Quebec, Sept. 15, 2017

Donates More than $2 Million in Medicines and Health Care Products

LAVAL, Quebec, Sept. 15, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") today announced the Company and its employees through a matching donation program will donate $200,000 to the American Red Cross to support its efforts in the areas affected by Hurricanes Harvey and Irma. Additionally, Valeant has worked with Americares to donate more than $2 million of critically needed medicines and over-the-counter health care products to people in need in these areas.

"Our thoughts and prayers are with the people of Texas, the Gulf Coast and Florida, including some of our employees, who have been impacted by these destructive storms," said Joseph C. Papa, chairman and CEO, Valeant. "We are glad to support both the American Red Cross and Americares. Additionally, I am especially proud of the response by our employees, some of whom traveled to the affected areas to volunteer in the relief efforts."

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at

Investor Contact:                                

Media Contact:

Arthur Shannon                                            

Lainie Keller              

(514) 856-3855                                                 

(908) 927-0617

(877) 281-6642 (toll free)                     





View original content with multimedia:

SOURCE Valeant Pharmaceuticals International, Inc.

PR Newswire

Last updated on: 15/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.